Today’s AI Top Pick: PODD

7/9/2026 · Recently Alerted Turnaround screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Recently Alerted TurnaroundPODDBUY NOW8.6 / 107/9/2026

PODD (Insulet) is the cleanest 'recently-alerted turnaround' setup in the pool: it passes the fundamental screen with a fundamental_score of 8 (epsNextY +24.63%, salesYoY +31.93%, ROE 23, profitMargin 10.44, recom 1.43) AND the multi-timeframe tape confirms with unusual force. Forecasts stack up across every horizon: 1d fc_short +18.68% / mid +70.84% / long +57.07%; 4h mid +48.14% / long +86.05%; 1wk mid +69.10% / long +82.87%. Bullish_prob is 1.0 with near_term_bullish 0.8 — that is genuine multi-timeframe agreement, not a single-bar outlier. Crucially, this is not a chase. Weekly drawdown from the 21-bar high is -36.69% and position in the weekly 21-bar range is only 11%, so we are buying a beaten-down leader (perfYear -46.9%) that is just beginning to base rather than one already ripping into resistance (compare YMM at 96% of daily range or TIGR at 100% on 1h). On the 1h the pullback is fresh (pos 3.9%, dd -4.32%) which offers a tight tactical entry without giving up the larger swing thesis. Fundamentals also justify a full position rather than a rental. Insulet is a diabetes-device grower with 71.6% gross margin, expanding into Europe (Omnipod 5 launched in Spain 7/7) and analysts already project 24.6% forward EPS growth on a 19.5 fwdPe. The 7/8 analyst target cut headline is a mild negative but the accompanying commentary and the 7/7 'could beat earnings estimates again' piece net out constructive — no guidance cut, no legal overhang, no dilution. Contrast that with FUTU (DOJ probe + class actions), STEP (Hunterbrook short report flagging a $2.3B liability), ZG (FTC trial with Redfin) and TMDX (analyst target cut with -51% weekly DD still deteriorating). PODD's news is the tamest of any name with comparable forecast magnitudes. Why today and not wait: the 1h has already backed off (pos 3.9%, dd -4.32%) so you get a favorable risk/reward without missing the move — daily and weekly forecasts still call for 57–83% upside over the mid/long horizon. Waiting means either buying higher after the daily fc_short +18.68% plays out or missing it entirely if the base resolves.

Entry zone

$154–158 (current $156.13, buy into any dip toward $152 on intraday weakness)

Stop loss

$142 (below the recent 1h/4h swing and roughly 8–9% risk; a break there invalidates the base)

First target

$182–188 (fills the 1d fc_short +18.68% and reclaims prior 4h consolidation)

Longer target

$240–260 (aligns with 1d fc_mid +70.84% and 1wk fc_long +82.87%; approx analyst target upside +50.3%)

Risks

Analyst target was just cut on 7/8 — sentiment can still fade further before it turns; a second cut would break the thesis
Weekly drawdown of -36.69% shows a still-broken longer-term trend; needs to reclaim the weekly 21-bar mid before institutions re-engage
Short float 7.11% and instOwn 105.37% mean crowded ownership — an earnings miss would unwind quickly
Fwd P/E 19.5 on a device maker with 10.4% net margin leaves little cushion if salesYoY decelerates from 31.93%
Healthcare/medtech reimbursement or FDA headline risk could hit sentiment independent of company execution

Honorable mentions

HSAIFund score 8, prob 1.0, near_term 1.0, 1d forecasts +26–33%, epsNextY +68.61%, salesYoY +44.14%, positive lidar headlines, and mid-range positioning (pos 43% on 1d). Only knock: weekly forecasts are anemic (+2.30/+1.38) so the swing case is weaker than PODD's.

CHWYMulti-tf alignment is real (1d fc +22.67/+48.79/+39.59, 1wk +3.64/+83.85/+68.77), ROE 63.82, TD Cowen top-2026-pick catalyst on 7/7. Held back by weaker fundamental_score (6.5), thin 1.99% profit margin, and daily pos already at 80.95% (a bit extended).

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.6	Multi-tf agreement, 1wk fc +82% long, deep DD -36% with pos only 11% weekly, fund score 8, only mild target-cut news.
2	HSAI	BUY NOW	8.0	Prob 1.0/near-term 1.0, 1d fc +26–33%, epsNextY 68.6%, positive lidar coverage — weekly forecasts weak is the only blemish.
3	CHWY	BUY NOW	7.7	1wk fc mid +83.85%, ROE 63.8, TD Cowen top-2026 pick catalyst; slightly extended intraday but weekly base intact.
4	CALX	BUY NOW	7.4	Fund 8, 4h fc long +59.92%, new AI platform customer, pos 1h at 0% = fresh dip; class-action headline is minor overhang.
5	ORCL	BUY NOW	7.2	Mega-cap with roe 54.3/profit 25.2, RSI 28.7 washout, 1d pos 0.81% and fc mid +31% — quality name at max pain.
6	TMDX	BUY PULLBACK	6.9	1d fc +52.7/+68.6/+57.1 and 4h long +135%, but recent analyst target cut and -51% weekly DD argues for patience.
7	ZG	BUY PULLBACK	6.6	Huge 1wk fc mid +100%, near-term 1.0, but FTC trial with Redfin and pe 128 cap upside on any news miss.
8	MAT	BUY PULLBACK	6.3	1wk fc long +51.6%, deep DD, pos near 0 across tfs; the 1h +3168% forecast is a single-bar outlier to ignore.
9	BILI	BUY PULLBACK	6.1	1wk fc mid +109%, buyback catalyst, but prob only 0.6 and 1h pos just 2.9% — wait for confirmation.
10	CELH	BUY PULLBACK	5.9	Prob 0.8/near-term 1.0, salesYoY 123%, UBS Buy reiteration; short float 20.7% and negative single-day tape argue for patience.
11	SRAD	BUY PULLBACK	5.6	epsNextY 69.8%, but 4h pos at 97.8% and 1h/1wk forecasts negative — good story, wrong entry point.
12	MNTN	BUY PULLBACK	5.3	1d fc mid +42%/long +56%, but prob is null and pos at 94% weekly is chase territory.
13	YMM	BUY PULLBACK	5.2	Upgrade to Buy headline, but pos 96.78% on 1d = fully extended; wait for a 5–8% pullback.
14	TIGR	BUY PULLBACK	5.1	1d fc +80%, salesYoY 48%, but 1h/4h pos at 100/98% — momentum is already priced.
15	SE	BUY PULLBACK	5.0	Analyst upgrade catalyst and RSI 68.8, but pos 100% on 4h and 1d = classic chase; better on a dip to 4h mid.
16	MLCO	BUY PULLBACK	4.7	1wk fc +50% mid, peg 0.16 cheap; Morgan Stanley just downgraded to EW, needs new catalyst.
17	INTR	BUY PULLBACK	4.6	peg 0.24, salesYoY 50%, but 1wk fc mixed and pos 1h already at 95%.
18	BX	WAIT	4.4	Large-cap quality but forecast magnitudes modest (1d mid +13.9%), best only as a lower-vol allocation.
19	NOW	WAIT	4.2	Near-term_bullish only 0.4 and 1h fc mid -12.25% — the setup is not yet confirmed.
20	HNI	WAIT	4.0	1h/4h forecasts negative, StockStory 'plummet' headline, pe 91 with 0.04% profit margin — too fragile.
21	RBBN	WAIT	3.8	Nice 4h/1wk mid forecasts but salesYoY -1.15% and operMargin 0.64% — no fundamental support.
22	PGY	WAIT	3.5	Screen-perfect fundamentals (recom 1, peg 0.2) but 4h fc -10.86% and 1wk fc short -26% — tape is fighting the thesis.
23	SPOT	WAIT	3.3	fwdPe 27, forecast magnitudes modest, no clean drawdown edge — no reason to be first in line.
24	PWP	WAIT	3.1	salesYoY -30.35% undercuts the turnaround narrative; recom 2 already at the screen limit.
25	OPFI	WAIT	2.8	Bullish_prob only 0.2 with debtEq 3.98 — screen looks good but signal disagrees.
26	TOST	WAIT	2.5	Near-term_bullish 0.2 and negative headlines on 7/8; Barclays initiation not enough to offset weak tape.
27	SDA	AVOID	2.4	pe 500, $91M cap, forecast magnitudes are noise not signal (1wk long +944%) — uninvestable.
28	PSIX	AVOID	2.2	1wk fc long -60.73% flatly contradicts the daily bull case — the swing thesis breaks on the longer tf.
29	FUTU	AVOID	2.0	DOJ probe and class-action headlines are exactly the landmine to avoid despite strong fundamentals.
30	STEP	AVOID	1.5	Hunterbrook short report flagging $2.3B liability; ROE -750, operMargin -45% — do not catch this knife.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord